Akvaforsk Genetics

akvaforskgenetics.com

Akvaforsk Genetics is the leading provider of technical genetic improvement services to aquaculture industries worldwide. We have extensive experience in design, implementation and routine technical operation from more than 25 applied selective breeding programs for fish and crustacean species in Europe, Asia and Latin America. These programs cover the majority of the commercially important farmed aquaculture species, including salmonids, tilapias, marine fish and shrimp. We routinely conduct external reviews of third party broodstock management and breeding program operations.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

APTORUM GROUP JOINS THE BEAM ALLIANCE TO COMBAT ANTIMICROBIAL RESISTANCE

Business Wire | September 08, 2020

news image

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the “BEAM Alliance”) as full member. The BEAM Alliance is a network of approximately 70 small and medium-sized European companies...

Read More

MEDTECH

AMPEL BIOSOLUTIONS' PRECISION MEDICINE BREAKTHROUGH PREDICTS DRUG OPTIONS WITH RNA ANALYTICS & MACHINE LEARNING

AMPEL BioSolutions | July 07, 2022

news image

AMPEL BioSolutions announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer. Revealed at the Precision Medicine World Conference in Silicon Valley California, the first-in-class platform technology utilizes RNA analytics and machine learning to characterize an individual's gene expression and provide clinical decision support to physicians for tre...

Read More

CELL AND GENE THERAPY

DISCOVERY LIFE SCIENCES LAUNCHES GMP COMPLIANT DISCOVERY LEUKOPAKS™ TO ACCELERATE RESEARCH AND DEVELOPMENT OF CELL AND GENE THERAPIES

Discovery Life Sciences | October 28, 2020

news image

Discovery Life Sciences™ (Discovery), a global leader in biospecimen, genomic sequencing, cell, and immunohistochemistry (IHC) services, announces the launch of GMP-compliant Discovery Leukopaks™ and other cell-based products for use in human cell and gene therapy research, development and manufacturing programs. Cell and gene therapies have revolutionized treatment approaches to cancer and other complex diseases. Acceleration of the manufacturing and development of these novel thera...

Read More

INDUSTRIAL IMPACT

LYGOS AND FLEXIBLE SOLUTIONS INTERNATIONAL ANNOUNCE REGISTRATION STATEMENT ON FORM S-4 RELATED TO PROPOSED MERGER

Lygos Inc | July 26, 2022

news image

Lygos Inc., a vertically integrated biotechnology provider of sustainable specialty ingredients, and Flexible Solutions International Inc. a developer and manufacturer of biodegradable products, today announced that FSI has filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on July 25, 2022 in connection with its proposed merger with Lygos. On April 18, 2022, Lygos and FSI announced a definitive merger agreement in an all-stock transaction ...

Read More
news image

APTORUM GROUP JOINS THE BEAM ALLIANCE TO COMBAT ANTIMICROBIAL RESISTANCE

Business Wire | September 08, 2020

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a biopharmaceutical company focused on novel therapeutics including the development of next-generation therapeutics targeting antimicrobial resistance, today announced it joined the Biotech companies in Europe combating Antimicrobial Resistance Alliance based in Europe (the “BEAM Alliance”) as full member. The BEAM Alliance is a network of approximately 70 small and medium-sized European companies...

Read More
news image

MEDTECH

AMPEL BIOSOLUTIONS' PRECISION MEDICINE BREAKTHROUGH PREDICTS DRUG OPTIONS WITH RNA ANALYTICS & MACHINE LEARNING

AMPEL BioSolutions | July 07, 2022

AMPEL BioSolutions announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer. Revealed at the Precision Medicine World Conference in Silicon Valley California, the first-in-class platform technology utilizes RNA analytics and machine learning to characterize an individual's gene expression and provide clinical decision support to physicians for tre...

Read More
news image

CELL AND GENE THERAPY

DISCOVERY LIFE SCIENCES LAUNCHES GMP COMPLIANT DISCOVERY LEUKOPAKS™ TO ACCELERATE RESEARCH AND DEVELOPMENT OF CELL AND GENE THERAPIES

Discovery Life Sciences | October 28, 2020

Discovery Life Sciences™ (Discovery), a global leader in biospecimen, genomic sequencing, cell, and immunohistochemistry (IHC) services, announces the launch of GMP-compliant Discovery Leukopaks™ and other cell-based products for use in human cell and gene therapy research, development and manufacturing programs. Cell and gene therapies have revolutionized treatment approaches to cancer and other complex diseases. Acceleration of the manufacturing and development of these novel thera...

Read More
news image

INDUSTRIAL IMPACT

LYGOS AND FLEXIBLE SOLUTIONS INTERNATIONAL ANNOUNCE REGISTRATION STATEMENT ON FORM S-4 RELATED TO PROPOSED MERGER

Lygos Inc | July 26, 2022

Lygos Inc., a vertically integrated biotechnology provider of sustainable specialty ingredients, and Flexible Solutions International Inc. a developer and manufacturer of biodegradable products, today announced that FSI has filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission on July 25, 2022 in connection with its proposed merger with Lygos. On April 18, 2022, Lygos and FSI announced a definitive merger agreement in an all-stock transaction ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us